BINEX Co., Ltd. (053030.KQ)
KRW 17490.0
(-3.95%)
KRW 17490.0
(-3.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 154.82 Billion KRW | -1.18% |
| 2022 | 156.67 Billion KRW | 16.58% |
| 2021 | 134.39 Billion KRW | 1.07% |
| 2020 | 132.97 Billion KRW | 6.16% |
| 2019 | 125.25 Billion KRW | 20.39% |
| 2018 | 104.04 Billion KRW | 33.34% |
| 2017 | 78.02 Billion KRW | -3.58% |
| 2016 | 80.92 Billion KRW | 13.76% |
| 2015 | 71.13 Billion KRW | 0.0% |
| 2013 | 57.29 Billion KRW | 3.93% |
| 2012 | 55.12 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 29.71 Billion KRW | -16.36% |
| 2024 Q2 | 31.47 Billion KRW | 5.93% |
| 2023 Q1 | 48.2 Billion KRW | 16.2% |
| 2023 Q2 | 39.5 Billion KRW | -18.04% |
| 2023 FY | 154.82 Billion KRW | -1.18% |
| 2023 Q3 | 31.59 Billion KRW | -20.01% |
| 2023 Q4 | 35.52 Billion KRW | 12.41% |
| 2022 Q4 | 41.48 Billion KRW | 4.94% |
| 2022 Q3 | 39.52 Billion KRW | -2.05% |
| 2022 Q2 | 40.35 Billion KRW | 14.28% |
| 2022 FY | 156.67 Billion KRW | 16.58% |
| 2022 Q1 | 35.31 Billion KRW | -11.22% |
| 2021 Q1 | 32.62 Billion KRW | -6.36% |
| 2021 Q2 | 28.58 Billion KRW | -12.38% |
| 2021 Q3 | 33.4 Billion KRW | 16.85% |
| 2021 Q4 | 39.77 Billion KRW | 19.05% |
| 2021 FY | 134.39 Billion KRW | 1.07% |
| 2020 Q2 | 33.98 Billion KRW | 8.98% |
| 2020 Q3 | 32.96 Billion KRW | -3.0% |
| 2020 Q4 | 34.84 Billion KRW | 5.71% |
| 2020 FY | 132.97 Billion KRW | 6.16% |
| 2020 Q1 | 31.18 Billion KRW | -6.7% |
| 2019 Q4 | 33.42 Billion KRW | 9.53% |
| 2019 Q2 | 31.94 Billion KRW | 8.76% |
| 2019 Q1 | 29.37 Billion KRW | -5.55% |
| 2019 FY | 125.25 Billion KRW | 20.39% |
| 2019 Q3 | 30.51 Billion KRW | -4.5% |
| 2018 Q2 | 24.05 Billion KRW | 8.27% |
| 2018 FY | 104.04 Billion KRW | 33.34% |
| 2018 Q4 | 31.1 Billion KRW | 16.63% |
| 2018 Q3 | 26.66 Billion KRW | 10.87% |
| 2018 Q1 | 22.21 Billion KRW | 21.88% |
| 2017 FY | 78.02 Billion KRW | -3.58% |
| 2017 Q3 | 19.63 Billion KRW | 3.64% |
| 2017 Q2 | 18.94 Billion KRW | -10.68% |
| 2017 Q4 | 18.22 Billion KRW | -7.17% |
| 2017 Q1 | 21.21 Billion KRW | 10.97% |
| 2016 Q2 | 19.66 Billion KRW | -4.7% |
| 2016 Q3 | 21.5 Billion KRW | 9.35% |
| 2016 Q4 | 19.11 Billion KRW | -11.11% |
| 2016 FY | 80.92 Billion KRW | 13.76% |
| 2016 Q1 | 20.63 Billion KRW | 30.88% |
| 2015 Q1 | 15.37 Billion KRW | 0.0% |
| 2015 Q4 | 15.76 Billion KRW | -16.21% |
| 2015 FY | 71.13 Billion KRW | 0.0% |
| 2015 Q3 | 18.81 Billion KRW | 13.5% |
| 2015 Q2 | 16.58 Billion KRW | 7.87% |
| 2014 Q1 | 14.35 Billion KRW | 25.02% |
| 2014 Q2 | 15.92 Billion KRW | 10.94% |
| 2014 Q3 | 14.96 Billion KRW | -5.99% |
| 2013 Q4 | 11.47 Billion KRW | -32.43% |
| 2013 Q1 | 12.38 Billion KRW | -15.28% |
| 2013 Q3 | 16.99 Billion KRW | 3.37% |
| 2013 Q2 | 16.43 Billion KRW | 32.66% |
| 2013 FY | 57.29 Billion KRW | 3.93% |
| 2012 Q3 | 11.95 Billion KRW | 0.0% |
| 2012 Q4 | 14.62 Billion KRW | 22.31% |
| 2012 FY | 55.12 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -260.892% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -1515.207% |
| Bioneer Corporation | 263.23 Billion KRW | 41.184% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -2281.828% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | -125.551% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -3073.508% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -3584.881% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 83.77% |
| Medy-Tox Inc. | 221.12 Billion KRW | 29.982% |
| Peptron, Inc. | 3.34 Billion KRW | -4532.846% |
| Amicogen, Inc. | 159.9 Billion KRW | 3.177% |
| Genexine, Inc. | 4.42 Billion KRW | -3397.579% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | -188.051% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -353.425% |
| ALTEOGEN Inc. | 96.52 Billion KRW | -60.402% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 40.683% |
| SillaJen, Inc. | 3.93 Billion KRW | -3830.003% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | -163.684% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -807.304% |
| Genomictree Inc. | 3.41 Billion KRW | -4429.677% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -728.958% |
| EASY BIO,Inc. | 165.38 Billion KRW | 6.385% |
| GI Innovation, Inc. | 5.31 Billion KRW | -2810.87% |